Home Featured 2

Featured 2

Featured posts

Random

Treating Patients with MET Alterations: A Q&A with Dr. Ravi Salgia

lungcanc

PACIFIC Flooded Us with Optimism. Now What?

Making Headway with Lorlatinib

Evolution of Research Using Patient-Reported Outcomes in Lung Cancer: A Q&A With Dr. Benjamin Movsas

JAVELIN Lung 200: Potential Reasons for Avelumab’s Failure to Provide OS Benefit

The IASLC Pathology Committee Recommendations for the Use of Diagnostic Immunohistochemistry...

lungcanc

Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s...

lungcanc

Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in...

lungcanc

Financial Incentives and Free Treatment Aids for Smoking Cessation in the...

lungcanc

ICU Care for the Patient with Lung Cancer

lungcanc

Smoking Cessation Prior to Lung Cancer Surgery

lungcanc

Q&A with Lead ALCHEMIST Investigator, Dr. Ramaswamy Govindan

lungcanc

Histologic Transformation From NSCLC to SCLC: A Mechanism of Resistance to...

lungcanc

Paul Bunn

The Peaks and Valleys in Lung Cancer Therapeutics Research

lungcanc

NCI Director Dr. Norman E. Sharpless Discusses 2019 Budget Plans During...

lungcanc

12 3...7 Page 1 of 7

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib